0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Aspirin Effects on Mortality and Morbidity in Patients With Diabetes Mellitus:  Early Treatment Diabetic Retinopathy Study Report 14

Aaron Kassoff, MD; Sheldon M. Buzney, MD; J. Wallace McMeel, MD; John J. Weiter, MD, PhD; Gerald J. Doyle, MD; Rodney L. Immerman, OD; Gerald R. Friedman, OD; Michael L. Klein, MD; Richard Dreyer, MD; Richard Chenoweth, MD; Irvin Handelman, MD; Richard Hohl, MD; Robert Biesbroeck, MD; Jack Sipperley, MD; Charles A. Garcia, MD; Michael A. Bloome, MD; Richard S. Ruiz, MD; F. Tempel Riekhof, MD; William A. Bohart, MD; Roy A. Goodart, MD; Dana H. Clarke, MD; David H. Orth, MD; Timothy P. Flood, MD; Kirk H. Packo, MD; Jayant Malhotra, MD; Akbar Rahmani, MD; Edward J. Winter, MD; Harish Bhatia, MD; Robert P. Murphy, MD; Stuart L. Fine, MD; Michael J. Elman, MD; Frederick L. Ferris III, MD; Thaddeus E. Prout, MD; Arnall Patz, MD; Thomas A. Rice, MD; David Newsome, MD; Lloyd M. Aiello, MD; Lawrence I. Rand, MD; Sabera T. Shah, MD; Ramachandiran Cooppan, MD; Jerry Cavallerano, OD, PhD; Robert Poole, OD; Philip Silver, OD; Jose Briones Jr, MD; Mohammed Z. Wafai, MD; Abdul C. Asmal, MD, PhD; Rudolph M. Franklin, MD; Laurence Arend, MD; Donald Bergsma, MD; Lance Turkish, MD; Paul Beer, MD; Denis Carroll, MD; Edgar Thomas, MD; Thomas C. Burton, MD; Gary W. Abrams, MD; Hak-Joong Kim, MD; George A. Williams, MD; Trexler M. Topping, MD; Frederick H. Reeser, MD; Thomas M. Aaberg, MD; Gregory S. Brinton, MD; James K. Kingham, MD; Travis A. Meredith, MD; Raymond R. Margherio, MD; Patrick L. Murphy, MD; Morton S. Cox, MD; Michael Trese, MD; Steven Winokur, MD; Everett Ai, MD; Robert Sorenson, MD; Gary Arsham, MD; John Cavender, MD; Stanley M. Kopelow, MD; Alan L. Shabo, MD; Jose C. Briones Jr, MD; Richard D. Hornichter, MD; Norman P. Blair, MD; Morton F. Goldberg, MD; C. Ronald Lindberg, MD; Neil L. Ross, MD; Lynn E. Hauser, MD; Jose Cunha-Vaz, MD, PhD; J. Terry Ernest, MD, PhD; James C. Liang, MD; Steven B. Cohen, MD; Charles Vygantas, MD; Gerald Williams, MD; Harry W. Flynn Jr, MD; George W. Blankenship, MD; William H. Knobloch, MD; Robert C. Ramsay, MD; Herbert L. Cantrill, MD; Frederick C. Goetz, MD; Byron Hoogwerf, MD; José Berrocal, MD; Raúl Pérez, MD; A. Ramos Umpierre, MD; James L. Kinyoun, MD; Robert E. Kalina, MD; Craig G. Wells, MD; Steven V. Guzak, MD; Jerry Palmer, MD; Frank L. Myers, MD; George H. Bresnick, MD; Suresh R. Chandra, MD; Matthew D. Davis, MD; Ronald Klein, MD; Thomas S. Stevens, MD; Ingolf H. Wallow, MD; Russell Dixon, MD; Edward Ehrlich, MD; Robin Ewart, MD; Robert N. Frank, MD; Stephenie Lucas, MD; Fred Whitehouse, MD; Harold Weiss, MD; Ann E. Ballen, MD; Michael Teske, MD; Maria Warth, MD; William E. Benson, MD; William S. Tasman, MD; Gary C. Brown, MD; J. Archibald McNamara, MD; Hunter L. Little, MD; Robert L. Jack, MD; Lawrence Basso, MD; Dayton T. Miller, PhD; Elaine Gunter; David D. Bayse, PhD; W. Harry Hannon, PhD; James E. Myrick, PhD; Genell L. Knatterud, PhD; Marian R. Fisher, PhD; Mary Jane Prior, PhD; Franca Barton, MS; Joseph Kufera, MA; Thomas W. Miller, MS; James K. Hooper, MS; Richard S. Crow, MD; Richard R. Baker, MD; Ronald Prineas, MBBS, PhD; Larry D. Hubbard, MAT; Yvonne L. Magli; Paul Segal, MD; Richard L. Mowery, PhD; Emily Y. Chew, MD; Daniel G. Seigel, ScD; Gary Cassel, MD
JAMA. 1992;268(10):1292-1300. doi:10.1001/jama.1992.03490100090033.
Text Size: A A A
Published online

Objectives.  —This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS).

Study Design.  —This multicenter, randomized clinical trial of aspirin vs placebo was sponsored by the National Eye Institute.

Patients.  —Patients (N=3711) were enrolled in 22 clinical centers between April 1980 and July 1985. Men and women between the ages of 18 and 70 years with a clinical diagnosis of diabetes mellitus were eligible. Approximately 30% of all patients were considered to have type I diabetes mellitus, 31% type II, and in 39% type I or II could not be determined definitely.

Intervention.  —Patients were randomly assigned to aspirin or placebo (two 325-mg tablets once per day).

Main Outcome Measures.  —Mortality from all causes was specified as the primary outcome measure for assessing the systemic effects of aspirin. Other outcome variables included cause-specific mortality and cardiovascular events.

Results.  —The estimate of relative risk for total mortality for aspirin-treated patients compared with placebo-treated patients for the entire study period was 0.91 (99% confidence interval, 0.75 to 1.11). Larger differences were noted for the occurrence of fatal and nonfatal myocardial infarction; the estimate of relative risk was 0.83 for the entire follow-up period (99% confidence interval, 0.66 to 1.04).

Conclusions.  —The effects of aspirin on any of the cardiovascular events considered in the ETDRS were not substantially different from the effects observed in other studies that included mainly nondiabetic persons. Furthermore, there was no evidence of harmful effects of aspirin. Aspirin has been recommended previously for persons at risk for cardiovascular disease. The ETDRS results support application of this recommendation to those persons with diabetes at increased risk of cardiovascular disease.(JAMA. 1992;268:1292-1300)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();